Pharmacokinetic considerations for new targeted therapies.
about
ABC transporters in multi-drug resistance and ADME-Tox of small molecule tyrosine kinase inhibitors.Use of antineoplastic agents in patients with cancer who have HIV/AIDS.Contribution of tumoral and host solute carriers to clinical drug response.Tumor penetration and epidermal growth factor receptor saturation by panitumumab correlate with antitumor activity in a preclinical model of human cancerContribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronideAdvances in cancer therapeuticsRitonavir and efavirenz significantly alter the metabolism of erlotinib--an observation in primary cultures of human hepatocytes that is relevant to HIV patients with cancer.Uptake carriers and oncology drug safety.Tyrosine kinase inhibitors as modulators of ATP binding cassette multidrug transporters: substrates, chemosensitizers or inducers of acquired multidrug resistance?Optimizing oncology therapeutics through quantitative translational and clinical pharmacology: challenges and opportunities.Enhancing value of clinical pharmacodynamics in oncology drug development: An alliance between quantitative pharmacology and translational science.Harnessing Solute Carrier Transporters for Precision Oncology.Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors.Contribution of ABCC4-mediated gastric transport to the absorption and efficacy of dasatinib.Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transportersIntegrating clinical pharmacology concepts in individualized therapy with tyrosine kinase inhibitors.Kinase Inhibitors: The Reality Behind the Success.Development and validation of an analytical method for regorafenib and its metabolites in mouse plasma.
P2860
Q35171274-CCD07A86-223F-42B0-A069-77EE8A627167Q35932561-E64AAFFE-BEFA-47BC-A68F-539FDD0C2FB6Q35946876-7A992F03-499D-4992-81C1-E02B8FF1E0ECQ36402296-E99271D5-98C3-417B-9DA4-2A89F0B85787Q36698681-DD1A7E57-8994-4C58-9167-C31401B908BDQ37069339-7400D389-160B-46E3-BEDB-1F81C8827B2AQ37193103-135D64F3-FCDD-4B72-BE28-14B2EFD57E36Q37663396-FF8F73E8-DA1C-49DD-8911-180E95FFBC10Q37853578-0A64D933-EF79-47EE-AF1D-05FD04CF048AQ38351470-DA0D3FB8-07DA-46A5-8A98-ADF5A95701F3Q38996431-A17D3995-D560-4AD7-9EAC-6EF7FB7950E2Q39204754-DC54D43D-D2B7-4CF9-9833-1F22D7786708Q41276800-202A3D9D-165C-4395-849E-C64480BEBE22Q41763725-37499B89-E8F3-46E4-9B67-B92AA6A3561EQ41808513-A855FBD3-4C2D-43A3-BD02-1457E59C8113Q43451983-E3C4661C-457D-445C-A264-41A4762ED059Q47970146-DEF143B5-9907-4F3B-8012-1DF68227204CQ54108364-49CE3E1A-6E33-4DC5-BAA4-3AB6524ABEBA
P2860
Pharmacokinetic considerations for new targeted therapies.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 17 December 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pharmacokinetic considerations for new targeted therapies.
@en
Pharmacokinetic considerations for new targeted therapies.
@nl
type
label
Pharmacokinetic considerations for new targeted therapies.
@en
Pharmacokinetic considerations for new targeted therapies.
@nl
prefLabel
Pharmacokinetic considerations for new targeted therapies.
@en
Pharmacokinetic considerations for new targeted therapies.
@nl
P2860
P356
P1476
Pharmacokinetic considerations for new targeted therapies
@en
P2860
P304
P356
10.1038/CLPT.2008.242
P407
P577
2008-12-17T00:00:00Z